
An indicative vote taken on Wednesday by the CHMP, an expert panel that is part of the European Medicines Agency, did not result in a majority in favor of recommending Orphazyme’s candidate arimoclomol for approval in the region. The CHMP (Committee for Medicinal Products for Human Use) was considering arimoclomol for the indication Niemann Pick type C, a rare metabolic disease also known as NPC.
The company reported the results of this vote itself after being summoned to a meeting with the committee to answer questions about the drug.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app